跳至主要内容
临床试验/CTRI/2024/10/075954
CTRI/2024/10/075954招募中不适用

Pesticide Measurement in Breast Cancer Tissue

HealthCare Global Enterprises Ltd.1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2024年11月15日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
10
试验地点
1
主要终点
Presence or absence of pesticides in the breast tissue

研究概览

简要总结

  • Recurrent inflammation caused by any carcinogenic agent such as bacteria, virus,

-Tobacco or pesticide is the underlying pathophysiology of cancer formation.

Inflammation caused by obesity is a major attributor of breast carcinoma.

-However, the influence of local accumulation of Pesticides-an inflammatory carcinogenic agent that specifically has affinity for fatty tissue is underlooked.

  • Food items such as poultry, fish, meat, and dairy products serve as sources of exposure for these pesticides through the diet. It is also secreted in cow’s milk and human breast milk,and has been detected in household dust and air.

  • Oc tend to accumulate in adipose tissue when compared with blood, and breast samples predict the level of oc exposed over time.

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 70.00 Year(s)(—)
性别
Female

入选标准

  • Pathologically confirmed Breast cancers of all morphologies.

排除标准

  • Non malignant breast tumors.

结局指标

主要结局

Presence or absence of pesticides in the breast tissue

时间窗: One time at the time of sampling

次要结局

  • Component analyses of pesticides(one time, at the time of sampling)

研究者

发起方
HealthCare Global Enterprises Ltd.
申办方类型
Private hospital/clinic
责任方
Principal Investigator
主要研究者

Dr Krithikaa Sekhar

HealthCare Global Enterprises Ltd.

研究点 (1)

Loading locations...

相似试验

尚未招募
2/3 期
Ultra Hypo-fractionation In Carcinoma BreastNeoplasms,
CTRI/2024/10/076036Dr Ananya Nandi35
招募中
不适用
Circulating Tumor Cells as Biomarker for Monitoring Treatment Response After Surgery in Early Breast Cancer Patients -Towards Improving Patient Well BeingMalignant neoplasm of nipple and areola, (2) ICD-10 Condition: C501||Malignant neoplasm of central portion of breast, (3) ICD-10 Condition: C502||Malignant neoplasm of upper-innerquadrant of breast, (4) ICD-10 Condition: C503||Malignant neoplasm of lower-innerquadrant of breast, (5) ICD-10 Condition: C504||Malignant neoplasm of upper-outerquadrant of breast, (6) ICD-10 Condition: C505||Malignant neoplasm of lower-outerquadrant of breast, (7) ICD-10 Condition: C506||Malignant neoplasm of axillary tail of breast, (8) ICD-10 Condition: C509||Malignant neoplasm of breast of unspecified site,
CTRI/2025/09/094661Dr Rakesh S Ramesh48
招募中
2 期
A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast CanceBRCA1/2 Mutation or NotPlatinum-sensitiveTNBC, Triple Negative Breast Cancer
NCT07321015Tianjin Medical University Cancer Institute and Hospital72
招募中
不适用
Ultrasound, Immunology and Genomics for Understanding Therapy Response in Breast CancerMalignant neoplasm of breast of unspecified site,
CTRI/2025/07/091416Indian Institute of Technology Hyderabad68
尚未招募
不适用
A clinical trail to study the significance of serum prostrate specific antigen in breast cancer patients In belagavi , Karnataka - A one year observational study .Malignant neoplasm of breast,
CTRI/2025/08/092485Dr Gaddam Rishitha24
Measuring levels of pesticides in Breast Cancers. | 临床试验